Dipyridamole (tablet): Difference between revisions
No edit summary |
No edit summary |
||
Line 44: | Line 44: | ||
|fdaLIADAdult= | |fdaLIADAdult= | ||
===== | =====Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement===== | ||
* Dosing Information | * Dosing Information | ||
:* | :* The recommended dose is 75-100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants. | ||
=====Condition2===== | =====Condition2===== |
Revision as of 22:35, 13 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Dipyridamole (tablet) is a platelet aggregation inhibitor that is FDA approved for the {{{indicationType}}} of postoperative thromboembolic complications of cardiac valve replacement. Common adverse reactions include chest pain, electrocardiogram abnormalities, flushing, rash, abdominal discomfort, dizziness, headache, and dyspnea.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement
- Dosing Information
- The recommended dose is 75-100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Condition2
- Dosing Information
- Dosage
Condition3
- Dosing Information
- Dosage
Condition4
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Dipyridamole (tablet) in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Dipyridamole (tablet) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Dipyridamole (tablet) in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Dipyridamole (tablet) in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Dipyridamole (tablet) in pediatric patients.
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Dipyridamole (tablet) in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Dipyridamole (tablet) in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dipyridamole (tablet) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Dipyridamole (tablet) during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Dipyridamole (tablet) with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Dipyridamole (tablet) with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Dipyridamole (tablet) with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Dipyridamole (tablet) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Dipyridamole (tablet) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Dipyridamole (tablet) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Dipyridamole (tablet) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Dipyridamole (tablet) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Dipyridamole (tablet) in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Dipyridamole (tablet) in the drug label.
Condition1
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Dipyridamole (tablet) in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Dipyridamole (tablet) in the drug label.
Pharmacology
There is limited information regarding Dipyridamole (tablet) Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Dipyridamole (tablet) in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Dipyridamole (tablet) in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Dipyridamole (tablet) in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Dipyridamole (tablet) in the drug label.
Condition1
- Description
How Supplied
Storage
There is limited information regarding Dipyridamole (tablet) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Dipyridamole (tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Dipyridamole (tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Dipyridamole (tablet) in the drug label.
Precautions with Alcohol
- Alcohol-Dipyridamole (tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Persantine®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ "DIPYRIDAMOLE tablet, film coated".
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Dipyridamole (tablet) |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage= |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Dipyridamole (tablet) |Label Name=Dipyridamole (tablet)11.png
}}
{{#subobject:
|Label Page=Dipyridamole (tablet) |Label Name=Dipyridamole (tablet)11.png
}}